BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of its Novel Universal Flu Vaccine Candidate
March 13, 2018 at 10:27 AM EDT
BiondVax Pharmaceuticals developer of the Universal Flu Vaccine candidate M-001, announced today the signing of a Master Service Agreement with a contract research organization to conduct the first pivotal, clinical efficacy, Phase 3 trial of M-001.
